Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis

In this cohort study of biologic-naive patients with UC initiating advanced therapy, the burden of hospitalization did not differ significantly between patients receiving vedolizumab and those receiving a TNF agonist; however, a vedolizumab-first strategy was associated with a greater proportion of time spent in corticosteroid-free disease stability over 5 years than a TNF antagonist–first strategy. These findings may inform first-line treatment selection in UC.

Corresponding Author: Siddharth Singh, MD, MS, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, AZ SC 238E-6, Scottsdale, AZ 85259 (singh.siddharth@mayo.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.